Galectin Therapeutics Inc. (GALT) Financials

GALT Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 14.8 million 151.7 million
March 31, 2026 15.8 million 146.0 million
Dec. 31, 2025 19.5 million 145.7 million
Sept. 30, 2025 12.9 million 138.2 million

GALT Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -2.4 million 963000
March 31, 2026 -3.9 million 686000
Dec. 31, 2025 -6.0 million 195000
Sept. 30, 2025 -3.5 million 496000

GALT Net Income

No data available :(

GALT Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 13.3 million - -
March 31, 2026 14.1 million - 6000
Dec. 31, 2025 17.7 million - 22000
Sept. 30, 2025 11.5 million - 37000

GALT Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 65.9 million
March 31, 2026 65.8 million
Dec. 31, 2025 63.9 million
Sept. 30, 2025 64.2 million

GALT Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 2.1 million 1.8 million -
March 31, 2026 - 2.2 million 1.8 million -
Dec. 31, 2025 - 1.9 million 1.4 million -
Sept. 30, 2025 - 2.6 million 1.6 million -

GALT Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 12000
Dec. 31, 2025 - -12000
Sept. 30, 2025 - -

GALT

Price: $3.62

52 week price:
2.03
7.13

Earnings Per Share: -0.45 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 205300

Ebitda: -4.4 million

Market Capitalization: 238.1 million

Links: